The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.
Male or female, age ranging from 18 to 70 years old (excluding 70 years old);
body weight ≥45 kg;
Histologically or cytologically confirmed diagnosis of malignant solid tumor;
Solid tumor patients who receive a 3-week chemotherapy regimen have been evaluated as high-risk for FN or evaluated as having moderate risk for FN, but with an increased risk factor for neutropenia associated with the chemotherapy regimen;(The risk assessment of FN in tumor chemotherapy is based on " Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy related neutropenia(2021 edition)" and " Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China(2023 edition)";
Received any other PEG-rhG-CSF within 4 weeks prior to participating in this study;
Patients receiving intermittent or continuous chemotherapy regimens such as albumin paclitaxel and capecitabine;
Previously or expected to receive extensive radiation therapy (>25% of total bone marrow);
Pregnant or breastfeeding woman ;
Solid tumor patients who require chemotherapy (chemotherapy regimen for FN high-risk or FN medium risk accompanied by increased risk factors)
Other
Prospective
Telpegfilgrastim Injection
DrugWithin 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.
The incidence of grade ≥3 neutropenia during four chemotherapy cycles
Click on the lead sponsor to view all of their trials.
